ResearchSafe

Sandoz ships first generic GLP-1 in the UK, here's why the pricing actually matters

Posted by weekendnate in Research & News - 2 points, 5 comments.

Saw this one land this week and it's a bigger deal than most headlines make it sound. Sandoz pushed out the first generic liraglutid injectable in the UK at around a 60 percent discount to brand Victoza, which is the first real market entry we've seen outside of Saxenda's patent expiry noise. The big question for anyone who has been priced out or rationing doses is whether this pressure finally cascades into the US market, because the FDA has been sitting on applications forever.

What caught my eye is the biosimilar pathway angle. Peptide hormones are way more complex to copy than small molecules, so a clean generic here suggests the manufacturing side is maturing. If Wegovy and Mounjaro follow the same curve, the obesity treatment landscape genuinely changes in the next few years, not just in theory.

For me, the interesting part is what it does to compounded pharmacy economics once the brand pricing finally collapses. Anyone else watching the UK rollout closely, or think I'm reading too much into a single approval?

Comments

  • fasted_scientist: Ngl the biosimilar point is the bit worth unpacking, but I'd push back slightly on the "bigger deal" framing. Liraglutide is older tech, the writing's been on the wall for years. What's actually interesting is whether the FDA bottleneck breaks because if the US follows the UK lead on approval timelines, compounded pharmacies get squeezed properly. That matters for this space because a lot of grey market stuff flows through cheaper compounding when brand names are eyewatering. The 60 percent dis
  • elle_z: Yeah the NHS vs US insurance thing is such a, the discount kinda lives in a different universe depending on which system you are in. And true, liraglutide feels like the warm-up act. The compounding squeeze angle is what i keep coming back to too, if real biosimilars actually land in the US the grey stuff has nowhere to hide 😅
  • lena_gains: Fair pushback on the framing, imo you're right that liraglutide isn't the exciting part, it's the approval pathway test. The compounding squeeze angle is what I keep coming back to too. If the FDA actually clears a wave of these, the grey market argument loses a lot of its justification real fast.
  • weekendnate: Yeah, that's exactly it. The pathway matters more than the molecule here. And if Sandoz cleared whatever bioequivalence bar they had to hit, that's a signal to every other manufacturer sitting on applications that the bar isn't impossible. The compounding argument gets real thin when legit generics are sitting on the shelf at a fraction of the cost, and a lot of the "access" justification starts to fall apart. Curious if you've seen any movement on the Wegovy generic timeline, because that's th
  • weekendnate: Totally with you on the compounding angle, that's the part I'm watching most. The grey market only exists because brand pricing is irrational and supply is thin, so real generics at sane numbers should squeeze it out fast. Liraglutide feels like the proof of concept honestly, if they can scale that to semaglutide the whole equation flips.
  • weekendnate: Yeah fair, I was probably overselling it. Liraglutide being older does dull the shine a bit. The NHS procurement caveat is the part I glossed over too, US PBMs and formulary negotiations are a whole different animal so the 60 percent figure probably doesn't translate cleanly. The compounding squeeze angle is what I'm watching now actually, if the FDA actually clears those backlogged applications the grey market math changes overnight. Did you see anything on timeline for the Wegovy biosimilar r

Community discussion - research and educational context only. Not medical advice.